Rifampicin for multiple system atrophy
- PMID: 24507092
- PMCID: PMC6200132
- DOI: 10.1016/S1474-4422(14)70022-5
Rifampicin for multiple system atrophy
Erratum in
- Lancet Neurol. 2014 Apr;13(4):346
Comment on
-
Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2014 Mar;13(3):268-75. doi: 10.1016/S1474-4422(13)70301-6. Epub 2014 Feb 5. Lancet Neurol. 2014. PMID: 24507091 Free PMC article. Clinical Trial.
References
-
- Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) Journal of the neurological sciences. 1989;94(1–3):79–100. - PubMed
-
- Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience letters. 1998;251(3):205–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
